Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $251.4 million.

  • CG Oncology's Change in Acquisitions & Divestments rose 2491.56% to $251.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $850.1 million, marking a year-over-year increase of 1375.75%. This contributed to the annual value of $745.4 million for FY2024, which is 8803.78% up from last year.
  • Per CG Oncology's latest filing, its Change in Acquisitions & Divestments stood at $251.4 million for Q3 2025, which was up 2491.56% from $170.4 million recorded in Q2 2025.
  • CG Oncology's 5-year Change in Acquisitions & Divestments high stood at $251.4 million for Q3 2025, and its period low was $30.7 million during Q3 2023.
  • In the last 3 years, CG Oncology's Change in Acquisitions & Divestments had a median value of $200.1 million in 2025 and averaged $180.9 million.
  • Over the last 5 years, CG Oncology's Change in Acquisitions & Divestments had its largest YoY gain of 55635.68% in 2024, and its largest YoY loss of 80.98% in 2024.
  • Over the past 3 years, CG Oncology's Change in Acquisitions & Divestments (Quarter) stood at $230.0 million in 2023, then dropped by 0.81% to $228.2 million in 2024, then rose by 10.17% to $251.4 million in 2025.
  • Its last three reported values are $251.4 million in Q3 2025, $170.4 million for Q2 2025, and $200.1 million during Q1 2025.